Condition
Early Stage Parkinson's Disease
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
80%
4 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (1)
P 3 (4)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00599196Phase 3CompletedPrimary
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
NCT00623324Phase 2CompletedPrimary
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
NCT00335374Phase 3CompletedPrimary
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
NCT00332917Phase 3CompletedPrimary
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
NCT00269516Phase 3CompletedPrimary
SLV308 for Treatment of Patients With Early Parkinson's Disease
Showing all 5 trials